Warren Paroly, MD
Hematology & Oncology · Oceanside, CANPI 1306981527
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,018, 2.3 times the $444 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 144 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$438
- Pfizer$201
- E.r. Squibb & Sons, L.L.C.$190
- Karyopharm Therapeutics Inc.$175
- Bristol Myers Squibb$163
- Daiichi Sankyo Inc.$160
- plus $2K from 33 others
Across 27 payments — averaging $431.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$7K
- Incyte Corporation$3K
- Pharmacyclics LLC, An Abbvie Company$2K
What the payments were for
- Food & beverage$3,34596%
- Education$1474%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 20 | $438 |
| Pfizer | 9 | $201 |
| E.r. Squibb & Sons, L.L.C. | 11 | $190 |
| Karyopharm Therapeutics Inc. | 7 | $175 |
| Bristol Myers Squibb | 8 | $163 |
| Daiichi Sankyo Inc. | 4 | $160 |
| Beigene USA, Inc. | 6 | $160 |
| AstraZeneca(2 entities) | 7 | $155 |
| Regeneron | 1 | $149 |
| Seagen Inc. | 7 | $145 |
| AbbVie | 5 | $118 |
| Coherus Oncology, Inc. | 4 | $109 |
| Lilly USA, LLC | 6 | $105 |
| GSK | 4 | $90 |
| Sanofi | 3 | $86 |
| Springworks Therapeutics, Inc. | 2 | $82 |
| Johnson & Johnson | 3 | $79 |
| Gilead(2 entities) | 4 | $79 |
| Array Biopharma Inc | 3 | $75 |
| Bayer | 4 | $73 |
| Novartis | 3 | $71 |
| Taiho Oncology, Inc. | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $52 |
| Servier Pharmaceuticals LLC | 2 | $47 |
| Puma Biotechnology, Inc. | 2 | $44 |
| Pharmaessentia USA Corporation | 1 | $35 |
| Beone Medicines USA, Inc. | 1 | $34 |
| Genentech USA, Inc. | 1 | $32 |
| Mirati Therapeutics, Inc. | 1 | $31 |
| Sobi, Inc | 1 | $30 |
| Blueprint Medicines Corporation | 1 | $26 |
| Deciphera Pharmaceuticals Inc. | 1 | $25 |
| Accord Healthcare, Inc. | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Legend Biotech USA Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $15 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$149
How this compares
$3,492 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 23 | $375,486 |
| BrukinsaZanubrutinib | 15 | $226,293 |
| XtandiEnzalutamide | 24 | $218,308 |
| CalquenceAcalabrutinib Maleate | 13 | $197,068 |
| Lenalidomide | 14 | $163,228 |
| AranespDarbepoetin Alfa In Polysorbat | 13 | $47,904 |
| Abiraterone Acetate | 11 | $37,050 |
| RetacritEpoetin Alfa-Epbx | 19 | $19,990 |
| Exemestane | 24 | $3,046 |
| Letrozole | 22 | $599 |
| Hydroxyurea | 15 | $451 |
| Prednisone | 30 | $244 |
| Acyclovir | 28 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $160 | $226,29315 claims |
| Astellas Pharma US IncXtandi | $52 | $218,30824 claims |
| AstraZenecaCalquence | $155 | $197,06813 claims |
| PfizerRetacrit | $201 | $19,99019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Oceanside
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.